There are many new non-interferon therapies currently unfolding for the treatment and cure of HCV. We offer novel trials for patients with various HCV genotypes and those with or without previous treatment.
Furthermore, the rate of progression to liver fibrosis and cirrhosis in HIV/HCV co-infected individuals is significantly shorter than in HCV mono-infection. Early treatment options are offered in our clinical trials along with studies addressing the complications of drug-drug interactions.
Community members interested in participating in a HCV study should contact the Screening Coordinator at (619) 543-8080.
Page 'Breadcrumb' Navigation: